Patents by Inventor Issiah B. Lozada

Issiah B. Lozada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11304958
    Abstract: Described herein is the development of synthetic routes to produce a wide variety of substituted phenanthridines, specifically, multidentate phenanthridine-containing ligand frameworks capable of anchoring to Pt via more than one binding site and with the phenanthridinyl moiety co-planar to the coordination plane of Pt. The multidentate chelation is designed to attenuate the reactivity of the platinum complex in vivo, and ultimately help mitigate side effects. In addition, the geometry of phenanthridine binding to the metal centre is altered compared to in phenanthriplatin, thanks to the constraints of the ligand geometry. By enforcing coplanar binding with the metal's square planar coordination plane, these compounds exhibit altered modes of activity, and should hence enhance/change the spectrum of activity of our prodrug candidates compared with phenanthriplatin.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: April 19, 2022
    Assignee: University of Manitoba
    Inventors: David E. Herbert, Issiah B. Lozada, Bin Huang, Yaorong Zheng, Zihan Qiu
  • Publication number: 20210052601
    Abstract: Described herein is the development of synthetic routes to produce a wide variety of substituted phenanthridines, specifically, multidentate phenanthridine-containing ligand frameworks capable of anchoring to Pt via more than one binding site and with the phenanthridinyl moiety co-planar to the coordination plane of Pt. The multidentate chelation is designed to attenuate the reactivity of the platinum complex in vivo, and ultimately help mitigate side effects. In addition, the geometry of phenanthridine binding to the metal centre is altered compared to in phenanthriplatin, thanks to the constraints of the ligand geometry. By enforcing coplanar binding with the metal's square planar coordination plane, these compounds exhibit altered modes of activity, and should hence enhance/change the spectrum of activity of our prodrug candidates compared with phenanthriplatin.
    Type: Application
    Filed: May 24, 2019
    Publication date: February 25, 2021
    Inventors: David E. Herbert, Issiah B. Lozada, Bin Huang, Yaorong Zheng, Zihan Qiu